DRUG News and Press, Bright Minds Biosciences Inc. From 06/23/23

2023-06-23 13:32:08 ET The U.S. Food and Drug Administration (FDA) published a new draft guidance on investigations into psychedelic drugs on Friday, detailing considerations for their clinical trials for the first time. The recommendations come at a time when there is growing public in...

2023-06-22 07:09:14 ET Bright Minds Biosciences ( NASDAQ: DRUG ) intends to consolidate its common shares on a five to one basis, whereby 18,860,359 common shares issued and outstanding will be converted into ~3,772,071 common shares issued and outstanding, The consolidation i...

VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatr...

2023-04-19 15:29:56 ET In the vast landscape of investment opportunities, penny stocks have emerged as an alluring option for those seeking high-risk, high-reward ventures. These low-priced stocks, particularly those under $1, offer the potential for exponential gains alongside the inhe...

-- BMB-202 is a highly selective 5-HT 2A agonist that exhibits a more than 30-fold selectivity over 5-HT 2C and more than 500-fold selectivity over 5-HT 2B -- -- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT 2A and 5-HT 2A/2C agoni...

— Presentation entitled "BMB-101: A selective 5-HT 2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 20...

Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) provided an update on its clinical programs , anticipated upcoming milestones, and strategic priorities for advancing its development pipeline of innovative treatments to heal the central nervous system (CNS) and brain through the regul...

-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT 2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, Mar...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASD...

Bright Minds Biosciences ( NASDAQ: DRUG ) said it had received a letter from the Nasdaq stating that following the resignation of Williamson from the company’s board of directors and audit committee, the Company no longer complies with its independent director and audit commit...